Previous 10 | Next 10 |
Equillium press release (NASDAQ:EQ): Q1 GAAP EPS of -$1.17. Cash and cash equivalents of $68.83M For further details see: Equillium GAAP EPS of -$1.17
Initiated EQUATOR Phase 3 study of itolizumab in first-line aGVHD Acquired Bioniz Therapeutics, adding two first-in-class clinical-stage assets to pipeline and proprietary product discovery platform Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that the European Hematology Association (EHA) has published an abstract high...
Itolizumab-induced reduction of CD6 from T effector cells promotes the development and activity of T regulatory cells CD6-ALCAM pathway confirmed as a target to prevent pathogenic T cell recruitment into inflamed organs Equillium, Inc. (Nasdaq: EQ), a clinical-stage ...
Itolizumab treatment associated with high rates of overall clinical response in the treatment of acute GVHD Clinical efficacy of itolizumab associated with higher serum concentrations after a single dose CD6 confirmed as a target to prevent pathogenic T cell recruitmen...
Translational data demonstrates itolizumab’s impact on effector T cell function in acute graft-versus-host disease Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflamma...
Equillium press release (NASDAQ:EQ): Q4 GAAP EPS of -$0.36 misses by $0.06. Cash, cash equivalents and short-term investments totaled $80.7 million as of December 31, 2021, compared to $82.2 million as of December 31, 2020. For further details see: Equillium GAAP EPS of -$0.36 misses by...
Announced positive topline data from EQUATE study of itolizumab in first-line aGVHD Initiated EQUATOR Phase 3 study of itolizumab in first-line aGVHD Presented interim safety data and reduction in proteinuria from the EQUALISE study of itolizumab in lupus patients ...
Response at Day 29 was associated with 72% overall survival at 12 months and high rates of progression-free survival 7 9% of responders maintained or achieved a complete response through at least 6 months Responders were able to taper corticosteroids by 73% at Day ...
Equillium (NASDAQ:EQ) began a phase 3 trial of its drug itolizumab in patients with acute graft-versus-host disease (aGVHD). GVHD is an inflammatory response by the immune system after a bone marrow transplant. The disease can be caused after the immune cells of the donor attack the recipient...
News, Short Squeeze, Breakout and More Instantly...
Q2 ending cash, cash equivalents and short-term investments totaled approximately $33.3 million, an increase of approximately $1.0 million compared to the amount at the end of Q1 Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutic...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will be participating in the Leerink Partners Therapeutic Forum: I&I and Metabolism, as well as the Jone...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it expects to join the Russell Microcap Index at the conclusion of the 2024 Russell annual reconstitution, effe...